Candyce H. Kroenke

Dr. Candyce H. Kroenke


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CKCandyce H. Kroenke
Candyce H. Kroenke
MKMarilyn L. Kwan
Marilyn L. Kwan
ANAlfred I. Neugut
Alfred I. Neugut
IEIsaac J. Ergas
Isaac J. Ergas
JWJaime D. Wright
Jaime D. Wright
LKLawrence H. Kushi
Lawrence H. Kushi

1 September 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
CKCandyce H. Kroenke
Candyce H. Kroenke
RNRomain Neugebauer
Romain Neugebauer
JMJeffrey Meyerhardt
Jeffrey Meyerhardt
CPCarla M. Prado
Carla M. Prado
EWErin Weltzien
Erin Weltzien
BCBette J. Caan
Bette J. Caan
Body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]) is positively associated with the risk of colorectal cancer (CRC).1-9 For that reason, investigators have hypothesized that being overweight or obese leads to worse CRC prognosis. However, though previous studies have shown an apparently elevated mortality risk in patients who are class II or III obese (BMI ≥35),10-12 associations of class I obesity (BMI 30 to <35) and survival are mixed; some studies show a higher mortality risk6,10,13-16 and others show no higher17 mortality risk or a possible lower18 mortality risk, depending in part on when BMI is measured relative to diagnosis. Patients who have CRC and are overweight or obese have shown lower mortality risks11,18 compared with patients who are normal weight or underweight when BMI is measured following diagnosis, but concerns are that the obesity paradox could reflect sample selection bias, reverse causality, and/or collider bias.19-21 We sought to employ methods to overcome these concerns in our evaluation of the effect of BMI on postdiagnosis mortality.

1 September 2012 in Menopause
Verified
Journal Article
Closed access
CKCandyce H. Kroenke
Candyce H. Kroenke
BCBette J. DrPH Caan
Bette J. DrPH Caan
MSMarcia L. Stefanick
Marcia L. Stefanick
GAGarnet Anderson
Garnet Anderson
RBRobert Brzyski
Robert Brzyski
RWRobert Wallace
Robert Wallace
Objective The aim of this study was to determine whether a dietary intervention designed to reduce fat intake and increase intake of fruit, vegetables, and whole grains, and weight loss, reduces vasomotor symptoms (VMS; ie, hot flashes or night sweats) in postmenopausal women. Methods We included 17,473 postmenopausal US women, ages 50 to 79 years, at baseline who participated in the Women’s Health Initiative Dietary Modification trial and were not taking menopausal hormone therapy. Logistic regression was used to evaluate associations. Results In multivariate-adjusted analyses, with simultaneous adjustment for the intervention and weight change, assignment to the dietary intervention versus the control arm was significantly (odds ratio [OR], 1.14; 95% CI, 1.01-1.28) related to a higher likelihood of symptom elimination among women with VMS at baseline. In addition, women with symptoms at baseline who lost 10 lb or more (OR, 1.23; 95% CI, 1.05-1.46) or lost 10% or more of their baseline body weight (OR, 1.56; 95% CI, 1.21-2.02) between baseline and year 1 were significantly more likely to eliminate VMS compared with those who maintained weight. Upon examining the joint effect of the dietary modification and weight loss, compared with women in the control arm who maintained weight, women who lost substantial weight (≥10%) as a part of the intervention (OR, 1.89; 95% CI, 1.39-2.57) but not as part of the control arm (OR, 1.40; 95% CI, 0.92-2.13) were significantly more likely to end VMS, although these two groups did not differ significantly from each other. Large weight loss (>22 lb), but not dietary changes, was related to the elimination of moderate/severe VMS. Conclusions Weight loss as part of a healthy dietary modification may help eliminate VMS among postmenopausal women.

10 November 2012 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CKCandyce H. Kroenke
Candyce H. Kroenke
CQCharles Quesenberry
Charles Quesenberry
MKMarilyn L. Kwan
Marilyn L. Kwan
CSCarol Sweeney
Carol Sweeney
ACAdrienne Castillo
Adrienne Castillo
BCBette J. Caan
Bette J. Caan

24 May 2018 in Cancer
Verified
Journal Article
Open access
PDF file
CKCandyce H. Kroenke
Candyce H. Kroenke
CPCarla M. Prado
Carla M. Prado
JMJeffrey A. Meyerhardt
Jeffrey A. Meyerhardt
EWErin K. Weltzien
Erin K. Weltzien
JXJingjie Xiao
Jingjie Xiao
BCBette J. Caan
Bette J. Caan
BACKGROUND: Low skeletal muscle radiodensity (SMD) is related to higher mortality in several cancers, but the association with colorectal cancer (CRC) prognosis is unclear.METHODS: This observational study included 3262 men and women from the Kaiser Permanente Northern California population diagnosed between 2006 and 2011 with AJCC stages I to III CRC. The authors evaluated hazard ratios (HRs) of low SMD for all‐cause and CRC‐specific mortality, assessed by computed tomography using optimal stratification, compared with patients with normal SMD. They also evaluated the cross‐classification of categories of low versus normal SMD and muscle mass (MM) with outcomes.RESULTS: The median follow‐up was 6.9 years. Optimal stratification cutpoints for SMD were 32.5 in women and 35.5 in men. In multivariate‐adjusted analyses, among patients with CRC, those with low SMD demonstrated higher overall (HR, 1.61; 95% confidence interval [95% CI], 1.36‐1.90) and CRC‐specific (HR, 1.74; 95% CI, 1.38‐2.21) mortality when compared with those with normal SMD levels. Patients with low SMD and low MM (ie, sarcopenia) were found to have the highest overall (HR, 2.02; 95% CI, 1.65‐2.47) and CRC‐specific (HR, 2.54; 95% CI, 1.91‐3.37) mortality rates.CONCLUSIONS: In patients with CRC, those with low SMD were found to have elevated risks of disease‐specific and overall mortality, independent of MM or adiposity. Clinical practice should incorporate body composition measures into the evaluation of the health status of patients with CRC. Cancer 2018;124:3008‐15. © 2018 American Cancer Society.

12 December 2016 in Cancer
Verified
Journal Article
Open access
PDF file
CKCandyce H. Kroenke
Candyce H. Kroenke
YMYvonne L. Michael
Yvonne L. Michael
EPElizabeth M. Poole
Elizabeth M. Poole
MKMarilyn L. Kwan
Marilyn L. Kwan
Sarah Jean NechutaSarah Jean Nechuta
Sarah Jean Nechuta
WCWendy Y. Chen
Wendy Y. Chen
BACKGROUND: Large social networks have been associated with better overall survival, though not consistently with breast cancer (BC)–specific outcomes. This study evaluated associations of postdiagnosis social networks and BC outcomes in a large cohort.METHODS: Women from the After Breast Cancer Pooling Project (n = 9267) provided data on social networks within approximately 2 years of their diagnosis. A social network index was derived from information about the presence of a spouse/partner, religious ties, community ties, friendship ties, and numbers of living first‐degree relatives. Cox models were used to evaluate associations, and a meta‐analysis was used to determine whether effect estimates differed by cohort. Stratification by demographic, social, tumor, and treatment factors was performed.RESULTS: There were 1448 recurrences and 1521 deaths (990 due to BC). Associations were similar in 3 of 4 cohorts. After covariate adjustments, socially isolated women (small networks) had higher risks of recurrence (hazard ratio [HR], 1.43; 95% confidence interval [CI], 1.15‐1.77), BC‐specific mortality (HR, 1.64; 95% CI, 1.33‐2.03), and total mortality (HR, 1.69; 95% CI, 1.43‐1.99) than socially integrated women; associations were stronger in those with stage I/II cancer. In the fourth cohort, there were no significant associations with BC‐specific outcomes. A lack of a spouse/partner (P = .02) and community ties (P = .04) predicted higher BC‐specific mortality in older white women but not in other women. However, a lack of relatives (P = .02) and friendship ties (P = .01) predicted higher BC‐specific mortality in nonwhite women only.CONCLUSIONS: In a large pooled cohort, larger social networks were associated with better BC‐specific and overall survival. Clinicians should assess social network information as a marker of prognosis because critical supports may differ with sociodemographic factors.Cancer2017;123:1228–1237.©2016 American Cancer Society.